Kian Huat (Eric) Lim (’ 06), a computational biologist, earned a spot on the 40 Under 40 in Cancer list — which recognizes emerging leaders in the study and treatment of cancer. Lim’s work at Stoke Therapeutics involves analyzing and understanding severe genetic diseases, including Dravet syndrome — a progressive developmental and epileptic disease that begins in childhood and is associated with high rates of sudden unexpected death in epilepsy. Stoke believes their investigational medicine has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome. Lim also is part of the collaborative COVID-19 International Research Team that analyzes data from COVID-19 patients.